



PATIENT

Sadie Bergman

SPECIES

Canine

BREED

German SH Pointer

SEX

Female Spayed

AGE

10 years

WEIGHT

51lbs

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

IMAGING PERFORMED BY

Jessica Miller, RDMS

HOSPITAL NAME

Summit Dog and Cat
Hospital

REFERRING VET

Dr. Chan

INVOICE

32473

DATE

8/22/23

PRESENTING CLINICAL SIGNS

History: Recheck echo.

-Current medications: Vetmedin 5mg 1 tab PO BID.

-Pertinent previous echo findings (1/2023 MML): Moderate to severe MR, mild to moderate LAE, mild LVE, trace TR: 2.0m/s. LA: 3.0, LV: 5.0

ECHOCARDIOGRAM FINDINGS

2D, m-mode, color flow and doppler imaging is available. Mild thickening of mitral valve leaflets (anterior>posterior) with marked prolapse into the left atrial lumen. Moderate eccentric mitral regurgitation with mild to moderate left atrial dilation. Normal MR velocity. Normal LV diameter with adequate myocardial function. The tricuspid valve appears normal with trace tricuspid regurgitation. Normal right atrial and ventricular diameter. The pulmonic and aortic valves are normal in morphology and mobility. Normal pulmonic and aortic outflow velocities. No aortic or pulmonic insufficiency. No pericardial or pleural effusion noted. No cardiac tumors observed. VPCs noted throughout (single lead ECG attached).

CARDIAC CHART

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
PATIENT	5.6	NM	1.3	1.5	46	90	0.3
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg: 2D and m-mode short axis (cm)	LVIDs Avg: 2D and m-mode short axis (cm)
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
PATIENT	120	2.2	0.95	23.1	3.0	4.1	2.2
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
BODY WEIGHT DEPENDENT PARAMETERS				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
*Note: All measurements based upon multi-modal images and methods. An average value is reported.				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
				35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
				40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
				50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

Chronic degenerative valve disease persists with evidence of stability. Moderate mitral and trace tricuspid regurgitation are unchanged, without progressive left heart enlargement. The LV dimension has improved, likely due to Pimobendan therapy. Persistently moderate left atrial enlargement indicates there is relatively low risk for imminent complication, however risk for progression to spontaneous congestive heart failure in the future is elevated. VPCs are noted throughout the study and a screening ECG is recommended. No additional issues are identified.



PATIENT

Sadie Bergman

Reasonable to continue Pimobendan lifelong as prescribed with no obvious indication for additional medications. Continued assessment of progression is recommended, with a guarded prognosis (stage B2). Patient may be at risk for development of CHF, arrhythmias, and/or sudden death going forward.

SPECIES

Canine

Omega fatty acid supplementation and mild salt restriction may also be of some long-term benefit. Monitor for development of a progressive cough, labored breathing, exercise intolerance or collapse episodes.

BREED

German SH Pointer

Anesthetic risk remains mildly elevated. Cardiac protective drug choices (opioid/benzodiazepine premedication, Propofol or alfaxalone induction, iso or sevo gas) are recommended. Monitor for arrhythmias, hypotension, and hypoxia both intra and post-operatively and intervene as necessary. Judicious IV fluid rates are recommended to avoid fluid overload. Avoid heart rate stimulating drugs such as atropine unless clinically indicated.

SEX

Female Spayed

AGE

10 years

PLAN

Baseline BP recommended every 6 months. Baseline ECG recommended. Continue Pimobendan 0.25-0.3mg/kg PO q12h.

WEIGHT

51lbs

Recommend monitor for progression with a recheck echocardiogram in 6 months, sooner if any development of clinical signs.

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

IMAGING PERFORMED BY

Jessica Miller, RDMS

HOSPITAL NAME

Summit Dog and Cat
Hospital

REFERRING VET

Dr. Chan


INVOICE

32473

DATE

8/22/23

IMAGES





PATIENT

Sadie Bergman

SPECIES

Canine

BREED

German SH Pointer

SEX

Female Spayed

AGE

10 years

WEIGHT

51lbs

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

**IMAGING
PERFORMED BY**

Jessica Miller, RDMS

HOSPITAL NAME

Summit Dog and Cat
Hospital

REFERRING VET

Dr. Chan

INVOICE

32473

DATE

8/22/23

The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

Maggie Machen Lamy, DVM
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)
info@sonopath.com